VAUGHAN & Co SECURITIES INC. Purchases 8,370 Shares of Pfizer Inc. (NYSE:PFE)

VAUGHAN & Co SECURITIES INC. lifted its position in Pfizer Inc. (NYSE:PFE) by 43.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 27,570 shares of the biopharmaceutical company’s stock after buying an additional 8,370 shares during the quarter. Pfizer comprises 0.5% of VAUGHAN & Co SECURITIES INC.’s investment portfolio, making the stock its 21st largest holding. VAUGHAN & Co SECURITIES INC.’s holdings in Pfizer were worth $771,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Navalign LLC lifted its holdings in shares of Pfizer by 6.2% during the second quarter. Navalign LLC now owns 12,245 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 717 shares during the last quarter. Searle & CO. lifted its holdings in shares of Pfizer by 121.9% during the second quarter. Searle & CO. now owns 111,697 shares of the biopharmaceutical company’s stock worth $3,125,000 after buying an additional 61,354 shares during the last quarter. Integral Investment Advisors Inc. raised its stake in shares of Pfizer by 35.6% in the second quarter. Integral Investment Advisors Inc. now owns 53,242 shares of the biopharmaceutical company’s stock valued at $1,480,000 after purchasing an additional 13,992 shares in the last quarter. Hantz Financial Services Inc. acquired a new position in shares of Pfizer in the second quarter valued at $10,782,000. Finally, Wolf Group Capital Advisors acquired a new position in shares of Pfizer in the second quarter valued at $211,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on PFE shares. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Wells Fargo & Company boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, August 19th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Up 1.0 %

NYSE PFE traded up $0.29 on Friday, reaching $29.01. The company had a trading volume of 37,137,599 shares, compared to its average volume of 38,496,418. The firm has a market capitalization of $164.39 billion, a price-to-earnings ratio of -483.50, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $36.29. The company’s fifty day moving average is $28.99 and its 200-day moving average is $28.01.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the business posted $0.67 EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis. On average, research analysts forecast that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.79%. Pfizer’s payout ratio is -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.